tislelizumab + bevacizumab + capecitabine

Tislelizumab + bevacizumab + capecitabine is an investigational triplet combination regimen being evaluated for the treatment of advanced solid tumors. The regimen combines tislelizumab, a humanized IgG4 monoclonal antibody that inhibits the PD-1/PD-L1 immune checkpoint; bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis; and capecitabine, an oral prodrug of 5-fluorouracil that acts as a cytotoxic antimetabolite. This combination is specifically being studied in the Phase Ib/II TIBEC trial to address immunotherapy resistance in PD-L1-negative triple-negative breast cancer (TNBC), hormone receptor-positive (HR+) breast cancer, and patients with active central nervous system (CNS) metastases. The therapeutic rationale is based on the synergistic potential of immune checkpoint blockade, anti-angiogenic therapy to normalize tumor vasculature, and chemotherapy-induced immunomodulation.

Other names

Tislelizumab, Bevacizumab, and Capecitabine